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Abstract
Prostate cancer is a prevalent, worldwide problem among male adults. This
literature review, “Examining the Efficacy of Screening with Prostate-Specific Antigen
Testing in Reducing Prostate Cancer Mortality,” focuses on a safe and effective
screening test for detecting prostate cancer in its early stages—prostate-specific antigen
testing—and seeks to answer the clinical question, “Does screening with PSA testing for
the early detection of prostate cancer in males ages 50-80 years significantly reduce
prostate cancer mortality?” A literature search of peer-reviewed articles within the last
fifteen years on databases such as CINAHL and Pub Med was conducted to find five
articles that pertained to the clinical question. An analysis and synthesis of the research
articles provided promising yet not conclusive evidence that prostate-specific antigen
testing significantly reduces the absolute risk of prostate cancer morality. Further
research is needed to provide more substantial evidence to support the use of prostatespecific antigen testing in clinical practice.
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Introduction
The efficacy of screening with prostate-specific antigen (PSA) testing for the
early detection of prostate cancer is a topic of heated debate in the medical world.
Articles have recently been published highlighting the harms and risks of PSA testing.
One of the most recent, a systematic review released by the U.S. Preventive Services
Task Force (USPSTF), reveals findings that confound the issue further. For example, the
USPSTF found PSA testing detects a modest amount of prostate cancers; however, it may
lead to overdiagnosis of prostate cancer and further risks such as pain secondary to
prostate biopsy (2008, pp. 185-187). In addition to this evidence, the USPSTF found
most prostate cancers detected with PSA testing will not be harmful to the patient during
their lifetime (2008, p. 187). Due to recently published articles and the 2008 positional
statement of the USPSTF, screening for prostate cancer has become a paradox. To
address the current debate about PSA testing and its role in screening for prostate cancer,
it is pertinent to ask the following: Does screening with PSA testing for the early
detection of prostate cancer in males ages 50-80 years significantly reduce prostate
cancer mortality?
Discussion of Prostate Cancer and Prostate Cancer Screening
The high prevalence of prostate cancer and the clinical importance of determining
whether current screening methods are effective in reducing prostate cancer mortality is
non-debatable. According to the World Health Organization (WHO), prostate cancer is
among the top five types of cancer that cause the majority of cancer fatalities (WHO,
2012). In the United States, prostate cancer is the second-leading cancer type, and in
2007, was one of the leading causes of cancer death among all men, yielding 29,093
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deaths related to prostate cancer (Centers for Disease Control and Prevention, 2011). As
prostate cancer remains a prevalent problem, it is pertinent to critically examine the
efficacy of the methods currently used to screen for prostate cancer.
Common methods used to screen for prostate cancer in the clinical setting include
both PSA testing and digital rectal exam (DRE). Prostate-specific antigen is a protein
produced by the prostate gland that is a biologic marker of prostate cancer as well as
benign prostate conditions (National Cancer Institute, 2009). PSA testing does not
distinguish between benign and cancerous prostate conditions; however, levels elevated
above set thresholds are a red flag for clinicians to pursue further testing (National
Cancer Institute, 2009). According to the American Urological Society (AUA), prostatespecific antigen testing remains the single best test to detect prostate cancer in its early
stages (2009, p.14). Furthermore, in combination with digital rectal examination, PSA
testing may detect prostate cancer in its early stages at even higher rates (AUA, 2009, p.
14). Why, then, is testing with PSA so controversial in practice? There are several
medical uncertainties associated with it.
First, there is great variability with the sensitivity and specificity of PSA testing.
At lower cutoff points for detecting prostate cancer, specificity is sacrificed for
sensitivity, increasing the risk of overdiagnosis. In addition to variable sensitivity and
specificity of PSA testing, clinical guidelines differ in their recommendations for
screening intervals and interpretations of test results. With no clear clinical pathway to
follow and the recent contradictory evidence of the benefits and risks of prostate cancer
screening with PSA testing, many clinicians have simply chosen to refrain from prostate
cancer screening, raising ethical concerns regarding a patient’s right to be screened. One
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must carefully review and critically appraise the current evidence of the efficacy of PSA
testing to determine whether it significantly reduces prostate cancer mortality.
Critical Analysis of the Evidence Related to the Clinical Question
Purpose
The studies by Andriole et al. (2009), Hugosson et al. (2010), Labrie et al. (1999a),
and Schröder et al. (2009) share a common purpose of determining the impact of
screening with prostate-specific antigen testing on prostate cancer mortality rates. The
study by Sandblom, Varenhorst, Lofman, Rosell, & Carlsson (2004) is an exception
because its purpose is to “to characterize prostate cancer detected in a population-based
screening program” (p. 718) as well as to evaluate the efficacy of screening with PSA at
three-year intervals. If the reader examines the primary outcomes measured in Sandblom
et al.’s (2004) study, the efficacy of PSA screening is measured in overall and cancerspecific survival rates, an outcome similar to the aforementioned studies. The purpose of
these studies reflects the purpose of the clinical question posed in this literature review.
Research design
The five research studies utilized one type of experimental design- randomized
controlled trials (RCT)-with varying strengths. The study designs were primarily clusterrandomized controlled trials, where pre-existing males from specific populations were
selected to be in either an intervention or control group. Of the randomized controlled
trials, Schröder et al. (2009) and Hugosson et al. (2010) had the strongest designs, with
large sample sizes, (power above .80), blinding to patient cause of death, and
randomization before consent, increasing the generalizability of the study findings. In
addition to these strengths, Schröder et al. (2009) utilized a central data center to ensure
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quality data was obtained for the duration of the study. Sandblom et al. (2004) also had
strengths, including randomization of participants prior to obtaining consent and control
for the extraneous variable of treatment received by participants with a positive prostate
cancer diagnosis. Strengths of Andriole et al.’s (2009) study included a large sample size
and control for the extraneous variable of prostate cancer screening in the control group.
A shared strength of all five studies was group equivalence, increasing the validity of the
studies. Despite the strengths of these studies, limitations existed, with Labrie et al.
(1999a), Andriole et al. (2009), and Sandblom et al. (2004) lacking a power analysis and
blinding in their studies. Design limitations of all five studies included an absence of
inter-rater reliability and instrumental validity scores as well as decreased generalizability
of study findings due to the increased control associated with the study designs.
Sampling
In all five of the research studies, older male adults without a previous or current
prostate cancer diagnosis represented the populations studied. Purposive, stratified
sampling was used to select the participants in each study. The population demographics
among the studies were fairly consistent, with high group equivalence due to
randomization of the study groups. All five studies had a male population, with ages
ranging from 50-69 (except Andriole et al. (2009) and Schröder et al. (2009), with upper
age limits in the mid to high 70s). Ethnicity was not included in the population
demographics for any of the five studies, consequently decreasing the external validity of
these studies’ findings. Attrition was addressed in some of the studies, with Schröder et
al. (2009), Hugosson et al. (2010), and Sandblom et al. (2004) appropriately discussing
the loss of their patients, which was largely due to immigration or death. The size of the
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study samples varied according to study designs and limitations, and only Schröder et al.
(2009) and Hugosson et al. (2010) justified their population size by a power analysis.
Despite the lack of detailed demographic description in the studies, the following clinical
and demographic characteristics of the studies, including lack of a previous or current
prostate cancer diagnosis, all male subjects, and an age range of 50-80 years are a
sufficient match for this literature review.
Variables
Prostate-specific antigen testing was the primary screening intervention utilized in
all of the studies with the exception of Sandblom et al. (2004), who chose to utilize the
combination of PSA testing and DRE. Schröder et al. (2009) and Labrie et al. (1999a)
also utilized digital rectal exam for prostrate cancer screening, however only for initial
screening, and then only PSA testing after that. Andriole et al. (2009) screened with PSA
and DRE separately, utilizing PSA testing for the first 6 years, then DRE for the last 4
years of their studies. Although the screening method was consistent in most of the
studies, the screening interval and PSA cutoff to signal further testing for prostate cancer
varied. Labrie et al. (1999a) and Andriole et al. (2009) both utilized an annual PSA
screening interval, with a PSA cutoff of >4.0 ng/ml in Andriole et al.’s study (2009), and
a PSA cutoff of >3.0 ng/ml in Labrie et al.’s (1999a) study. Conversely, Schröder et al.
(2009) conducted PSA testing every 4 years, with a PSA cutoff interval of >3.0- 4.0
ng/ml. Hugosson et al. (2010) screened for prostate cancer with a free/total PSA test
every 2 years, utilizing a PSA cutoff of >2.5-3.4 ng/ml for further diagnostic testing.
Sandblom et al. (2004) utilized a screening interval of 3 years, with a PSA cutoff of >4.0
ng/ml. The control used in all five studies was refraining from prostate cancer screening,
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which was theoretically achieved by the control group not receiving invitations to screen.
For the majority of the studies, the potential benefits of screening for prostate cancer
were worth the risks.
The primary outcome measure of all of the studies was prostate cancer mortality
(except Sandblom et al. (2004), the outcome of which was cancer-specific survival, an
indirect measure of mortality). In addition to the measure of prostate cancer mortality
rates, Hugosson et al. (2010) and Sandblom et al. (2004), examined the secondary
outcome of cumulative prostate cancer incidence, Schröder et al. (2009) determined the
number of people needed to screen and treat to prevent one prostate cancer-related death,
Labrie et al. (1999a) measured life-years gained by the diagnosis and treatment of
prostate cancer, and Andriole et al. (2009) determined the cost of prostate cancer
diagnosis as well as prostate cancer incidence, staging, and survival from prostate cancer.
Length of follow-up for measuring outcomes in the five studies varied, including 14 years
for Hugosson et al. (2010), 9 years for Labrie et al. (1999a) and Schröder et al. (2009), 15
years for Sandblom et al. (2004), and an interval of 7-14 years for Andriole et al. (2009).
Extraneous variables, whether known or detected, were present in all five studies.
A known extraneous variable for Andriole et al. (2009) and Labrie et al. (1999a) was
participation of the control group in prostate cancer screening, which was controlled for
in statistical analyses. Another known extraneous variable that was considered in the
2009 study design of Andriole et al. was the impact of different laboratory equipment on
the consistency of PSA results, therefore Andriole et al. (2009) processed all PSA results
through the same laboratory. Other known extraneous variables included bias related to
prostate cancer treatment (Sandblom et al., 2004; Schröder et al., 2009) and the impact of
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PSA testing as an established screening test on participant’s intention to screen (Labrie et
al., 1999a), which were considered in the study designs. Extraneous variables that
existed, but were not included in the studies included the impact of race on prostate
cancer risk (except in Andriole et al. (2009)) and the effect of varying personnel
administering digital rectal exams on the detection rate of prostate cancer. The failure to
address these extraneous variables decreases the internal validity of the studies.
Study measures
As mentioned in the previous section, the main outcome variable of the studies
was prostate cancer mortality. It was determined by utilizing death registries, cancer
registries, and mailed questionnaires. All five studies maintained a definition of prostate
cancer mortality as death directly caused by prostate cancer, or death as a result of
diagnostic procedures or treatments associated with prostate cancer. Cause of death was
determined by committee review of medical records (Hugosson et al., 2010; Sandblom et
al., 2004; Schröder et al., 2009), autopsy and pathology reports (Hugosson et al., 2010),
and death certificates (Andriole et al., 2009). All of the methods used to determine
prostate cancer mortality were established. Sandblom et al. (2004), however, were the
only authors that discussed the validity of the cancer register utilized to determine
mortality. With the exception of Sandblom et al. (2004), the other studies failed to
discuss the reliability and validity of the methods utilized to determine prostate cancer
mortality and survival rates as well as cause of death, weakening the internal validity of
their studies.
Statistical Analysis
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The statistical analyses used in the studies all differed from one another, yet each
researcher utilized descriptive and inferential statistics appropriately. A strength of all the
studies was their statistical significance levels were appropriately set at p ≤ .05. Andriole
et al. (2009) and Sandblom et al. (2004), however, did not always designate p values for
each finding, making their external validity questionable. The statistical analysis methods
utilized in the studies include the following: Poisson regression analysis (Andriole et al.,
2009; Hugosson et al., 2010; Schröder et al., 2009), Cox regression models (Hugosson et
al., 2010), the Nelsen-Aalen method (Hugosson et al., 2010; Schröder et al., 2009), a
Kaplan Meir estimator (Hugosson et al., 2010; Sandblom et al., 2004), two-sided Fisher’s
exact and Barnard’s tests (Labrie et al., 1999b), and log-rank tests (Sandblom et al.,
2004). All statistical tests utilized were appropriate for medical survival analysis as well
as detecting significant differences between the intervention and control groups. Despite
the appropriateness of these statistical analyses, their statistical conclusion validity is low
and their risk for type II error is high (except in Hugosson et al. (2010) and Schröder et
al.’s (2009) studies) because no official analysis to verify appropriate population size was
conducted (Andriole et al., 2009; Labrie et al., 1999a) or their p value was simply not
strong enough (Sandblom et al., 2004). The use of a power analysis and appropriate
statistical analysis methods makes Schröder et al. (2009) and Hugosson et al.’s (2010)
findings the highest in statistical conclusion validity.
Findings
With the utilization of PSA testing at regular intervals, a significant reduction in
the absolute risk for prostate cancer death after screening with PSA testing was found in
Schröder et al. (2009) and Hugosson et al.’s (2010) studies. Similarly, Labrie et al.
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(1999a) found regular PSA testing lead to a significant reduction in the incidence of
prostate cancer deaths. Contrary to these findings, Sandblom et al. (2004) did not find a
significant difference in prostate cancer-specific survival after screening with PSA testing
and Andriole et al. (2009) did not find a significant difference between the screening and
control groups in the reduction of prostate cancer mortality rates.
Additional findings included the number of people that need to be screened
(NNS) and treated (NNT) to prevent one prostate cancer-related death. Schröder et al.
(2009) found the NNS and NNT were 1068 and 48 people and Hugosson et al. (2010)
found the NNS and NNT were 293 and 12; numbers that appear significantly different,
yet are quite similar with ratios applied (22:1 and 24:1). Additionally, Hugosson et al.
(2010) found the control group had a significantly higher incidence of advanced prostate
cancer than the screening group and Schröder et al. (2009) found screening with PSA
testing significantly reduces the risk of diagnosis with metastatic prostate cancer.
Sandblom et al.’s (2004) findings also demonstrated a significantly lower incidence of
advanced tumor grades and metastases in the PSA testing intervention group than in the
control group. Conversely, Andriole et al. (2009) determined there was no significant
difference in the incidence of advanced (stage III of IV) prostate cancer in the screening
and control groups.
Other important results were related to the efficacy of screening with DRE and
the cost of PSA screening and diagnosis of prostate cancer. For example, Labrie et al.
(1999a) found that “14 percent of cancers were discovered by DRE in men with normal
PSA” levels, however, “5,000 DRE screenings are required to diagnose 1 case of prostate
cancer at follow-up visits” (p. 88). Labrie et al. (1999a) found the cost of screening and
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diagnosing prostate cancer is actually less expensive in comparison to the cost of
screening and diagnosing cervical and breast cancer. With the exception of Andriole et al.
(2009) and Sandblom et al.’s (2004) findings, the pattern of evidence in the studies
supports the effectiveness of prostate specific antigen screening in significantly reducing
prostate cancer mortality.
Synthesis “Answer” to the Clinical Question
An analytical review of the five research studies suggests that there is a moderate
amount of evidence that screening for prostate cancer utilizing PSA testing significantly
reduces the absolute risk of prostate cancer mortality. Although only three of the five
studies found PSA testing reduces prostate cancer mortality, the weight of evidence
comes from the clinical trials conducted by Schröder et al. (2009) and Hugosson et al.
(2010), as they have the highest level of statistical conclusion validity. Schröder et al.
(2009) found utilizing PSA testing every four years with a PSA cutoff value of 3-4 ng/ml
over a period of 9 years significantly reduces prostate cancer mortality. Hugosson et al.
(2010) determined screening for prostate cancer with PSA testing at 2 years intervals
with a PSA cutoff 2.5-3.4 over a 14-year period significantly reduces prostate cancer
mortality. Labrie et al.’s (1999a) study, although it lacks a power analysis, is another
strong contributor to the evidence-base for PSA screening because it is an RCT, used
valid measures, and had a large group size. Labrie et al. (1999a) discovered, in the initial
screening visit, digital rectal examination detected 14% of prostate cancers in men with
normal PSA levels, however the effectiveness of DRE declined in follow-up
appointments. Limitations of Schröder et al. (2009) and Hugosson et al.’s (2010) studies’
contribution to evidence-based practice is their lack of generalizability to the general
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population of older male adults secondary to their tightly controlled study designs.
Although the evidence provided by these studies is by no means conclusive, the
statistically significant findings of Schröder et al. (2009) and Hugosson et al. (2010)
demonstrate a need for replication or revision of these studies to provide further evidence
to support the use of prostate-specific antigen testing in clinical practice.
Implications for Practice
Although the findings of Hugosson et al. (2010) and Schröder et al. (2009) carry a
moderate weight of evidence supporting the use of PSA testing for prostate cancer
screening, it is of critical importance that the clinical implications of their findings are
carefully examined. It is crucial to consider how the findings of Hugosson et al. (2010)
and Schröder et al. (2009) should be applied in practice when deciding what type of
screening tests, screening intervals, and PSA cutoff points to utilize with prostate cancer
screening. The findings of Hugosson et al. (2010) and Schröder et al. (2009) suggest that
PSA testing used alone after the initial visit or throughout the course of testing is an
effective screening test in reducing prostate cancer mortality. Although selecting PSA
testing for prostate cancer screening is an initial step, the type of PSA test used in
screening should also be considered as it could greatly impact the specificity of the test’s
results (American Urological Association, 2009, p. 21). The American Urological Society
(AUA) has discovered the use of a free/total PSA ratio has been found to “reduce the
number of biopsies in men with serum PSA levels between 4.0 and 10.0 ng/ml”
(2009, p. 21). Theoretically, utilizing a free/total prostate ratio would then also reduce
unnecessary mental and physical harm to the patient as well. It is also imperative to
consider that the addition of DRE to PSA testing in the initial screening visit was found
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by Labrie et al. (1999a) to increase the sensitivity of screening for detecting prostate
cancer. Reflecting on these results, it would be appropriate to give patients the
recommendation for initially screening with DRE and a free/total PSA ratio, and then
solely using PSA testing to screen for prostate cancer thereafter.
In addition to the use of PSA testing as a primary prostate cancer screening test,
Hugosson et al. (2010) and Schröder et al. (2009) also suggest screening with PSA testing
at intervals of 2-4 years significantly reduces prostate cancer mortality. This is a very
broad range of screening intervals, and when applying these results to a patient, a
clinician must also consider whether the patient has a previous history of abnormal PSA
results, their personal and family history of prostate cancer, and their symptoms. While
the suggested screening interval of every 2-4 years suggests clinicians may be more
liberal with screening, clinicians should utilize a screening interval that is individualized
for the patient.
Hugosson et al. (2010) and Schröder et al. (2009) provide an evidence base for an
appropriate PSA threshold, an integral part of prostate cancer screening. The purpose of
PSA threshold or cutoff values is they suggest an increased risk of prostate cancer and a
need for further patient evaluation. Hugosson et al. (2010) and Schröder et al. (2009)
imply that a PSA cutoff range of 2.5-4 ng/ml is clinically effective in detecting prostate
cancer. This interval is fairly broad considering the difference of 1 ng/ml can
dramatically change the sensitivity and specificity of PSA tests in detecting prostate
cancer. The upper threshold of 4 ng/ml utilized by Schröder et al. (2009) has been found
to have a sensitivity of 20% and a specificity of 60-70% (AUA, 2009, pp. 20-22). To
increase the sensitivity and specificity of PSA tests, a lower PSA threshold for all men is
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suggested (AUA, 2009, pp. 20-22), such as that used by Hugosson et al. (2010). To
increase the specificity of PSA testing further, PSA thresholds can be age-adjusted, with
lower PSA threshold levels utilized for younger men (AUA, 2009, p. 19). Considering
the proven efficacy of the PSA thresholds utilized by Schröder et al. (2009) and
Hugosson et al. (2010) and the evidence from the American Urological Association
regarding the sensitivity and specificity of PSA thresholds, it would be advantageous for
clinicians to use lower, age-adjusted PSA threshold levels for all men, such as the
threshold of 2.5 ng/ml utilized by Hugosson et al. (2010).
Evidence regarding the length of follow-up for prostate cancer screening from
Hugosson et al. (2010) and Schröder et al.’s (2009) studies also has important
implications for clinical practice. Hugosson et al. (2010) and Schröder et al. (2009) found
at 9 and 14 years of follow-up for prostate cancer screening, prostate cancer mortality is
significantly reduced. These findings can be applied to clinical practice when clinicians
are trying to determine when to commence or halt prostate cancer screening if the years
of follow-up are viewed as male life expectancy. For example, if a an elderly man has a
life-expectancy of less than 9 years, it may be advantageous for the patient to stop PSA
testing, because the benefits of refraining from testing may outweigh the risks.
The evaluation of current evidence with high statistical conclusion validity
supports the use of prostate specific antigen testing in clinical practice to reduce prostate
cancer mortality. While the particular formulas of PSA thresholds, screening intervals,
and length of follow-up used by Schröder et al. (2009) and Hugosson et al. (2010) were
both effective in reducing prostate cancer mortality, they varied quite a bit, meriting
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consideration of further evidence such as recommendations from the American
Urological Association (2009) prior to application of the results to clinical practice.
Prostate cancer screening must be tailored to the individual, as their personal risk factors,
history, and treatment preferences may shape the course of screening. Finally, given the
strength of the evidence above, clinicians should at the very least offer their patients the
choice to be screened for prostate cancer with PSA testing, because PSA testing may
reduce their risk of developing advanced or even metastatic prostate cancer.
Patient Education
After a patient is offered the choice to screen for prostate cancer, they should be
presented with the current evidence regarding prostate cancer screening so they are well
equipped to make an informed decision. If the patient chooses to undergo screening, they
should be counseled that prostate cancer screening is tailored to the individual, with the
clinician considering the patient’s history, risk factors, life expectancy, and comfort level
for testing. The patient should be educated about the PSA test, the sensitivity and
specificity of PSA thresholds, screening intervals, and the next steps taken after a positive
PSA result (additional PSA tests and referral for fine-needle biopsy). Lastly, the clinician
should emphasize the patient is the key decision-maker for their plan of care, and
regardless of where the patient is in the screening process, the patient has the right to halt
or refuse screening and treatment.
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